Michael Cork

University of Sheffield

United Kingdom

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (20)

Collaborators (13)

Torsten Zuberbier

Mette Søndergaard Deleuran

Aarhus University

Thomas Bieber

JOHN CHITTOCK

University of Sheffield

UNITED KINGDOM

Elisabeth Riedl

Medical University of Vienna

Yuichiro Tsunemi

Ausama Atwan

Senior Clinical Lecturer

Cardiff University

UNITED KINGDOM

Mandy Wan

King’s College London

UNITED KINGDOM

Wojciech Francuzik

Charité - Universitätsmedizin Berlin

Andreas Wollenberg

Ludwig-Maximilians-Universität München

Jacob Pontoppidan Thyssen

Charlotte G. Mortz

Alan Irvine

Professor in Dermatology

Trinity College Dublin

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Michael Cork

Research Interests

Explore related searches

Contact this professor

Articles (20)

Collaborators (13)

Torsten Zuberbier

Mette Søndergaard Deleuran

Thomas Bieber

JOHN CHITTOCK

Elisabeth Riedl

Yuichiro Tsunemi

Ausama Atwan

Mandy Wan

Wojciech Francuzik

Andreas Wollenberg

Jacob Pontoppidan Thyssen

Charlotte G. Mortz

Alan Irvine

Make your next move.

Michael Cork

Research Interests

Explore related searches

Contact this professor

Articles (20)

Efficacy and safety of 308-nm Excimer lamp combined with Tacrolimus 0.1% ointment vs Tacrolimus 0.1% ointment as monotherapy in treating children with limited vitiligo: a randomized controlled trial

51363 Growth Analysis in Children Aged Less Than 12 Years with Moderate-to-Severe Atopic Dermatitis

52273 Dupilumab Provides Sustained Normalization of Skin Barrier Function in Children With Moderate-to-Severe Atopic Dermatitis

52650 Dupilumab Treatment Shows Rapid and Consistent Improvement in Atopic Dermatitis in All Anatomical Regions in Patients Aged 6 Months to 17 Years: Results From an Open-Label Extension Study

52909 MOISTURIZER WITH SKIN IDENTICAL LIPIDS RESTORES BARRIER FUNCTION IN ECZMEA-PRONE SKIN AND REDUCES SKIN SUSCEPTIBILITY TO IRRITANTS

53081 Dupilumab Treatment Provides Sustained Improvement in Skin Barrier Function, Clinical Outcomes, and Patient-Reported Outcomes in Patients Aged 6 to 11 Years With Moderate-to-Severe Atopic Dermatitis

701 - Dupilumab efficacy and safety up to 2 years in children aged 6 months to 5 years with atopic dermatitis

280 Children with atopic dermatitis respond more rapidly to dupilumab treatment in comparison to adolescents and adults

Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate‐to‐severe atopic dermatitis: Results from two terminated phase II trials

A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: results from the UK-Irish A-STAR register

Real-Time Infrared Spectroscopic Measurement of Natural Moisturizing Factor

Dupilumab improves patient-reported symptoms and health-related quality of life in children aged 6–11 years with severe atopic dermatitis

Early improvements in signs and symptoms predict clinical response to baricitinib in patients with moderate-to-severe atopic dermatitis

Developing integrated care pathways for atopic dermatitis—Challenges and unmet needs

Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis

Dupilumab Treatment Reduces Total IgE Levels in Patients 6 Months and Older with Moderate-to-Severe Atopic Dermatitis

Targeting skin barrier function in atopic dermatitis

337 Dupilumab treatment is not associated with an increased overall risk of infections in patients aged 6 months to 5 years with moderate-to-severe atopic dermatitis

345 Treatment with amlitelimab—a novel non-depleting, non-cytotoxic anti-OX40Ligand monoclonal antibody—reduces IL-22 serum levels in a phase 2a randomized, placebo-controlled trial in patients with moderate-to-severe atopic dermatitis

353 Amlitelimab reduces serum IL-13 in a phase 2a clinical trial in atopic dermatitis without impacting T-cell expansion in a T-cell recall assay

Collaborators (13)

Torsten Zuberbier

Mette Søndergaard Deleuran

Thomas Bieber

JOHN CHITTOCK

Elisabeth Riedl

Yuichiro Tsunemi

Ausama Atwan

Mandy Wan

Wojciech Francuzik

Andreas Wollenberg

Jacob Pontoppidan Thyssen

Charlotte G. Mortz

Alan Irvine

Make your next move.